Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 6/2010

01-06-2010 | Original paper

Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies

Authors: Elizabeth A. Platz, Siobhan Sutcliffe, Angelo M. De Marzo, Charles G. Drake, Nader Rifai, Ann W. Hsing, Ashraful Hoque, Marian L. Neuhouser, Phyllis J. Goodman, Alan R. Kristal

Published in: Cancer Causes & Control | Issue 6/2010

Login to get access

Abstract

Background

Data on long-term intra-individual variability in high-sensitivity C-reactive protein (hsCRP) are needed to determine whether one measurement adequately reflects usual levels in prospective studies of on the etiology of cancer and other chronic diseases; when not reflective, the ability to statistically detect modest to moderate associations is reduced. The authors estimated the size of this source of variability and consequent attenuation of the relative risk (RR).

Methods

High-sensitivity C-reactive protein (hsCRP) concentration was measured using a high-sensitivity immunoturbidometric assay in sera collected at years 2, 4, and 6 from 50 men in the placebo arm of the Prostate Cancer Prevention Trial (PCPT). After natural logarithm-transformation of hsCRP, analysis of variance was used to estimate the within- and between-individual variances from which the intra-class correlation coefficient (ICC) was calculated.

Results

The observed RR due to an ICC < 1 was calculated by e(ln true RR*ICC) for a range of true RRs. The 4-year ICC was 0.66. Measuring hsCRP once and assuming no other error, if the true RRs were 1.50, 2.00, and 3.00 when comparing high with low concentration, then the observed RRs would be 1.31, 1.58, and 2.06, respectively.

Conclusion

Investigators planning to measure hsCRP only once should design adequately sized studies to preserve inferences for hypothesized modest to moderate RRs.
Literature
1.
Tsimikas S, Willerson JT, Ridker PM (2006) C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47:C19–C31CrossRefPubMed
2.
Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA (2008) C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123:1133–1140CrossRefPubMed
3.
Rifai N, Ridker PM (2001) High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47:403–433PubMed
4.
Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224CrossRefPubMed
5.
Rosner B, Spiegelman D, Willett WC (1992) Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 136:1400–1413PubMed
6.
Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2–3-year period. Cancer Epidemiol Biomarkers Prev 4:649–654PubMed
7.
Clark GH, Fraser CG (1993) Biological variation of acute phase proteins. Ann Clin Biochem 30(Pt 4):373–376PubMed
8.
de Maat MPM, de Bart ACW, Hennis BC, Meijer P, Havelaar AD, Mulder PGH et al (1996) Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in health, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 16:1156–1162PubMed
9.
Macy EM, Hayes TE, Tracy RP (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43:52–58PubMed
10.
Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH et al (1999) Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 149:261–267PubMed
11.
Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47:444–450PubMed
12.
Nasermoaddeli A, Sekine M, Kagamimori S (2006) Intra-individual variability of high-sensitivity C-reactive protein: age-related variations over time in Japanese subjects. Circ J 70:559–563CrossRefPubMed
13.
Lee SA, Kallianpur A, Xiang YB, Wen W, Cai Q, Liu D et al (2007) Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev 16:2464–2470CrossRefPubMed
14.
Shemesh T, Rowley KG, Jenkins AJ, Best JD, O’Dea K (2009) C-reactive protein concentrations are very high and more stable over time than the traditional vascular risk factors total cholesterol and systolic blood pressure in an Australian Aboriginal cohort. Clin Chem 55:336–341CrossRefPubMed
15.
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230–235PubMed
16.
Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y et al (2000) Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993–1998. Jpn Circ J 64:303–308CrossRefPubMed
17.
Koenig W, Sund M, Frohlich M, Lowel H, Hutchinson WL, Pepys MB (2003) Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol 158:357–364CrossRefPubMed
18.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397CrossRefPubMed
19.
Al-Delaimy WK, Jansen EH, Peeters PH, van der Laan JD, van Noord PA, Boshuizen HC et al (2006) Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers 11:370–382CrossRefPubMed
20.
Glynn RJ, Macfadyen JG, Ridker PM (2009) Tracking of high-sensitivity C-reactive protein after observation of an initially increased concentration: the JUPITER Study. Clin Chem 55:305–312CrossRefPubMed
Metadata
Title
Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies
Authors
Elizabeth A. Platz
Siobhan Sutcliffe
Angelo M. De Marzo
Charles G. Drake
Nader Rifai
Ann W. Hsing
Ashraful Hoque
Marian L. Neuhouser
Phyllis J. Goodman
Alan R. Kristal
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 6/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9511-z

Other articles of this Issue 6/2010

Cancer Causes & Control 6/2010 Go to the issue

Original paper

Diabetes and risk of incident cancer: a large population-based cohort study in Israel

Original paper

Spatial Clustering of Myelodysplastic Syndromes (MDS) in the Seattle-Puget Sound Region of Washington State

Original paper

Alcohol and risk of breast cancer in Mexican women

Original paper

Estimation of cancer incidence and mortality attributable to smoking in China

Original paper

Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women

Original paper

Australian women’s awareness of breast cancer symptoms and responses to potential symptoms
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits